Fosaprepitant
Based on 4 publication(s) in Google Scholar
Fosaprepitant (L-785298) is a proagent of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 172673-20-0
- Fòrmula: C23H22F7N4O6P
- Peso molecular:614.41
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fosaprepitant
More
Actividad biológica
Neurokinin-1 receptor[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats[1]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection, daily, for 7 days
-
Result:Increased the antinociceptive effect of morphine compared to control group.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 172673-20-0
-
Peso molecular 614.41
-
Fòrmula C23H22F7N4O6P
-
SMILES
O=C1N=C(CN2[C@@H](C3=CC=C(F)C=C3)[C@@H](O[C@H](C)C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)OCC2)NN1P(O)(O)=O
-
Synonyms
L-758298
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
Antiemetic drug fosaprepitant exerts anti-tumor effects against NSCLC by targeting FAK to inhibit AKT and JNK/c-Jun pathways. [Abstract]2025 Sep 10. PMID: 40931041 -
Int J Biol Macromol
Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity. [Abstract]2026 Jun:369:152633. PMID: 42167430 -
Cancer Biol Ther
LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases. [Abstract]2019;20(5):653-665. PMID: 30582709 -
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fosaprepitant Related Classifications
HY-14407 Related Classifications
Powered by Bioz